We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully
Yahoo FinanceApr 15 06:03 ET
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
TipRanksFeb 15 14:25 ET
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?
TipRanksFeb 15 01:02 ET
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,The company's primary focus
BenzingaFeb 14 11:37 ET
Express News | Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Moomoo 24/7Feb 13 16:44 ET
Express News | Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Moomoo 24/7Feb 13 16:43 ET
Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB
Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB
Dow JonesFeb 13 16:07 ET
Express News | Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof
Moomoo 24/7Jan 11 06:42 ET
Buy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication Treatment
TipRanksNov 16, 2023 15:55 ET
Anebulo Pharmaceuticals GAAP EPS of -$0.10 Beats by $0.02
Seeking AlphaNov 15, 2023 08:49 ET
Anebulo Pharmaceuticals Q1 EPS $(0.10) Beats $(0.12) Estimate
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 9.09 percent increase over losses
BenzingaNov 14, 2023 16:59 ET
Rising Cannabis Hospitalizations and Leadership Transition Boost Anebulo Pharmaceuticals' Outlook: A Buy Rating Analysis
TipRanksOct 26, 2023 13:26 ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNkarta (NASDAQ:NKTX) shares moved upwards by 122.3% to $3.29 during Tuesday's regular session. Nkarta's stock is trading at a volume of 55.0 million shares as of 13:30 EST. This is 13383.6% of
BenzingaOct 17, 2023 13:31 ET
Purple Biotech, Nuwellis Among Healthcare Movers
Seeking AlphaOct 17, 2023 10:00 ET
MNTS, OMER and PIXY Among Mid-day Movers
Seeking AlphaOct 16, 2023 13:36 ET
Anebulo Pharmaceuticals Appoints New CEO
Anebulo Pharmaceuticals (ANEB) said Friday that it appointed Richie Cunningham as chief executive officer, succeeding Simon Allen. Cunningham has over 20 years of leadership experience, most recently
MT NewswiresOct 6, 2023 16:27 ET
Express News | Anebulo Pharmaceuticals Inc's Richie Cunningham Announced As Chief Executive Officer And Member Of Anebulo's Board Of Directors
Moomoo 24/7Oct 6, 2023 16:07 ET
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to Its Bd of Directors >ANEB
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to Its Bd of Directors >ANEB
Dow JonesOct 6, 2023 16:07 ET
Anebulo Pharmaceuticals : Richie Cunningham Has Been Appointed as Anebulo's Chief Executive Officer >ANEB
Anebulo Pharmaceuticals : Richie Cunningham Has Been Appointed as Anebulo's Chief Executive Officer >ANEB
Dow JonesOct 6, 2023 16:06 ET
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.
BenzingaOct 3, 2023 11:52 ET
No Data
No Data